您好,欢迎访问中山大学肿瘤防治中心官方网站!
内部网 职工邮箱 图书馆 OA系统 医生门户 English
院士风采 首席专家 临床专家 科研学者 人才名录 护理专家
首页
  • 曾维安

    职务:行政负责人、科主任导师
    职称:教授,主任医师,博士生导师
    专长:单肺通气,疼痛发病机制研究,神经病理性疼痛与癌痛的治疗
    基本情况
    职务:手术麻醉科行政负责人、主任导师
    职称:教授,主任医师,博士生导师
    教育及工作经历:
    1999年4月-至今 中山大学肿瘤防治中心,手术麻醉科
    1993年11月-1998年10月 日本岐阜大学,博士研究生
    1998年11月-1999年3月 日本岐阜大学医学部,研究学者
    1989年12月-1992年5月  日本名古屋大学医学部,研究生
    主攻方向: 
    1.单肺通气
    2.疼痛发病机制研究,神经病理性疼痛与癌痛的治疗
      曾维安,中山大学肿瘤防治中心手术麻醉科行政负责人,主任导师、教授、主任医师、博士生导师。
      从事临床麻醉研究与实践三十余年。先后主持五项国家自然基金面上项目和十余项省部级课题。发表高水平论文四十余篇,分别在Anesthesiology, JBC, BJA, J Pain, Ann Surg Oncol, Anesth Analg, iscience, Brain Behavior and Immunity等。

    一、指导研究生毕业
      截至2020年指导博士研究生13名,硕士研究生15名。在站博士后8名。

    二、主持科研项目
    1)2019-至今,国家自然科学基金课题,circ-Nrxn1/HIF-1α/NOX2轴调控脊髓小胶质细胞M1/M2极化介导化疗外周神经损伤的机制研究。
    2)2019.01-2021.12,临床科学家,中心高层次人才特殊支持项目。   
    3)2018-至今,国家重点研发计划,老年患者围手术期中枢神经系统常见并发症预警及综合防治技术研究。
    4)2016-2019,国家自然科学基金课题,疼痛炎性因子对NCX调节神经病理性疼痛的机制研究。
    5)2016.01-2018.12,临床科学家,中心高层次人才特殊支持项目。
    6)2013-2016,国家自然科学基金课题,NCX在神经病理性疼痛发病的作用和机制的研究。
    7)2013-2015,教育部博士点基金,钠钙交换蛋白在神经病理性疼痛机制的研究。 
    8)2013-2014 ,广东省科技计划项目,N-甲基-D-天冬氨酸受体抑制剂对肝细胞癌抑制增殖的作用及机制研究。
    9)2010-2012,国家自然科学基金课题,鞘内KB-R7943和SEA0400治疗神经病理性疼痛的研究。
    10)2006-2008,国家自然科学基金课题,鞘内哇巴因和阿米洛利治疗神经病理性疼痛的研究。
    11)2010-2012,广东省科技计划项目,鞘内KB-R7943和SEA0400治疗神经病理性疼痛的研究。
    12)2002 ,“985”专项基金 神经病理性疼痛基础和临床综合治疗的研究。
    13)2000-2002,国家教育部回国人员启动基金 脊髓内钙、钾通道在神经病理性疼痛中作用机理研究。

    三、指导的科研项目
    1)2011,广东省科技计划项目,钠钙交换蛋白在神经病理性疼痛中的表达。
    2)2010,广东省科技计划项目,肺复张/再灌注引起多器官氧化应激损伤的机制研究。
    3)2008,广东省卫生厅基金,吸入麻醉对大鼠海马乙酰胆碱释放昼夜节律的影响。  
    4)2008,广东省卫生厅基金,钠、钾泵抑制剂在脊髓内疼痛信号传递中作用的研究。
    5)2008,广东省科技计划项目,Na+-K+-ATP酶抑制剂哇巴因在脊髓内疼痛信号传递中作用的研究。
    6)2008,广东省科技计划项目,单肺通气致双侧肺非均一性损伤的机制及姜黄素干预作用的研究。

    四、发表论著
    1)Amide-type local anesthetics may suppress tumor cell proliferation and sensitize Human Hepatocellular Carcinoma Cells to Cisplatin via upregulation of RASSF1A expression and demethylation. Journal of Cancer.2020, 7312-7319.(*)
    2)Increased dopamine and its receptor dopamine receptor D1 promote tumor growth in human hepatocellular carcinoma. Cancer communications. 2020;1–17.(*)
    3)Expression of PD-L1 on Monocytes Is a Novel Predictor of Prognosis in Natural Killer/T-Cell Lymphoma. Front. Oncol. 10:1360.doi: 10.3389/fonc.2020.013602020 August. (*)
    4)JTC-801 alleviates mechanical allodynia in paclitaxel-induced neuropathic pain through the PI3K/Akt pathway. Eur J Pharmacol. 2020 Jun 27:173306. doi: 10.1016/j.ejphar.2020.173306. Online ahead of print. (*)
    5)Nuclear Factor-kappaB Gates Nav1.7 Channels in DRG Neurons via Protein-Protein Interaction. iScience. 2019 Aug 10;19:623-633. doi: 10.1016/j.isci.2019.08.017. [Epub ahead of print].
    6)Antinociceptive effectiveness of the inhibition of NCX reverse-mode action in rodent neuropathic pain model. Mol Pain. 2019 Jan-Dec;15:1744806919864511. doi: 10.1177/1744806919864511. (*)
    7)Sevoflurane promotes migration, invasion, and colony-forming ability of human glioblastoma cells possibly via increasing the expression of cell surface protein 44. Acta Pharmacol Sin. 2019 Apr 9. doi: 10.1038/s41401-019-0221-0. [Epub ahead of print].
    8)Puerarin Relieves Paclitaxel-Induced Neuropathic Pain: The Role of Nav1.8 β1 Subunit of Sensory Neurons. Front Pharmacol. 2019 Jan 7;9:1510. doi: 10.3389/fphar.2018.01510. eCollection 2018.
    9)Dexmedetomidine Protects Against Chemical Hypoxia-Induced Neurotoxicity in Differentiated PC12 Cells Via Inhibition of NADPH Oxidase 2-Mediated Oxidative Stress. Neurotox Res. Neurotox Res. 2019 Jan;35(1):139-149. doi: 10.1007/s12640-018-9938-7. Epub 2018 Aug 15. (*)
    10)The mu-opioid receptor is a molecular marker for poor prognosis in hepatocellular carcinoma and represents a potential therapeutic target. Br J Anaesth. 2019 Jun;122(6):e157-e167. doi: 10.1016/j.bja.2018.09.030. Epub 2018 Dec 12. (*)
    11)Bulleyaconitine A attenuates hyperexcitability of dorsal root ganglion neurons induced by spared nerve injury: The role of preferably blocking Nav1.7 and Nav1.3 channels. Mol Pain. 2018 Jan-Dec;14:1744806918778491. doi: 10.1177/1744806918778491.
    12)Amantadine attenuates sepsis-induced cognitive dysfunction possibly not through inhibiting toll-like receptor 2. J Mol Med (Berl). 2018 May;96(5):391-402.
    13)Calpain-2 Regulates TNF-α Expression Associated with Neuropathic Pain Following Motor Nerve Injury. Neuroscience. 2018 Feb 23;376:142-151. 
    14)Early CALP2 expression and microglial activation are potential inducers of spinal IL-6 upregulation and bilateral pain following motor nerve injury. J Neurochem. 2018 Feb 9. doi: 10.1111/jnc.14317. [Epub ahead of print].
    15)AKAP150 involved in paclitaxel-induced neuropathic pain via inhibiting CN/NFAT2 pathway and downregulating IL-4. Brain Behav Immun. 2018 Feb;68:158-168. 
    16)Synergistic Interaction Between Dexmedetomidine and Ulinastatin Against Vincristine-Induced Neuropathic Pain in Rats. J Pain. 2017 Nov;18(11):1354-1364.
    17)Down-regulation ofthe tumour suppressor κ-opioid receptor predicts  poor prognosis in hepatocellular carcinoma patients. BMC Cancer. 2017 Aug 18;17(1):553. (*)
    18)The Prognostic Value of Peripheral Benzodiazepine Receptor in Patients with Esophageal Squamous Cell Carcinoma. Journal of Cancer 2017, Vol. 8 2017; 8(16): 3343-3355. (*)
    19)Lidocaine Induces Apoptosis and Suppresses Tumor Growth in Human Hepatocellular Carcinoma Cells In Vitro and in a Xenograft Model In Vivo. Anesthesiology. 2017 May;126(5):868-881. (*)
    20)Internal jugular vein versus subclavian vein as the percutaneous insertion site for totally implantable venous access devices: a meta-analysis of comparative studies. BMC Cancer. 2016 Sep 22;16(1):747. (*)
    21)Prognostic value of pre-operative serum uric acid levels in esophageal squamous cell carcinoma patients who undergo R0 esophagectomy. Cancer Biomark. 2016 Jun 7;17(1):89-96. (*)
    22)Ulinastatin attenuates neuropathic pain induced by L5-VRT via the calcineurin/IL-10 pathway. Molecular Pain. Volume 12: 1–9. (*)
    23)Presynaptic N-Methyl-d-aspartate (NMDA) Receptor Activity Is Increased Through Protein Kinase C in Paclitaxel-induced Neuropathic Pain. J Biol Chem. 2016 Sep 9;291(37):19364-73.
    24)Fentanyl enhances hepatotoxicity of paclitaxel via inhibition of CYP3A4 and ABCB1 transport activity in mice. PLoS One. 2015 Dec 3;10(12):e0143701. (*)
    25)Spinal antinociceptive action of amiloride and its interaction with tizanidine in the rat formalin test. Pain Res Manag. 2015 Nov-Dec;20(6):321-6. (*)
    26)Antinociceptive effect of intrathecal amiloride on neuropathic pain in rats. Neurosci Lett. 2015 Jul 28;604:24-29. (*)
    27)Sevoflurane protects against intestinal ischemia-reperfusion injury partly by phosphatidylinositol 3 kinases/Akt pathway in rats. Surgery. 2015 May;157(5):924-33.
    28)Impact of preoperative anemia on relapse and survival in breast cancer patients. BMC Cancer. 2014 Nov 18;14:844.(*)
    29)Anti-inflammatory and antinociceptive activities of bufalin in rodents. Mediators Inflamm. 2014;2014:171839.(*)
    30)Long-term survival after resection of hepatocelluar carcinoma: a potential risk associated with the choice of postoperative analgesia. Anesth Analg. 2014 Jun;118(6):1309-16 (*)
    31)HSV-mediated p55TNFSR reduces neuropathic pain induced by HIV gp120 in rats through CXCR4 activity. Gene Ther. 2014 Mar;21(3):328-36.
    32)Mechanical allodynia induced by nucleoside reverse transcriptase inhibitor is suppressed by p55TNFSR mediated by herpes simplex virus vector through the SDF1α/CXCR4 system in rats. Anesth Analg. 2014 Mar;118(3):671-80.
    33)Real-time Two-dimensional Ultrasound Guidance for Central Venous Cannulation: A Meta-analysis. Anesthesiology. 2013 Feb;118(2):361-75. (*)
    34)The antinociceptive activity of intrathecally administered amiloride and its interactions with morphine and clonidine in rats. J Pain. 2012 Jan;13(1):41-8. (*) 
    35)The Beta2-Adrenergic Receptor is a Potential Prognostic Biomarker for Human Hepatocellular Carcinoma After Curative Resection. Ann Surg Oncol. 2012 Oct;19(11):3556-65. (*)
    36)The effects of anesthetic technique on cancer recurrence in percutaneous radiofrequency ablation of small hepatocellular carcinoma. Anesth Analg. 2012  Feb;114(2):290-6.
    37)The antinociceptive effect of intrathecal escin in the rat formalin test. Eur J Pharmacol. 2012 Jan 15;674(2-3):234-8. (*)
    38)Risk factors for anastomotic leakage following anterior resection for colorectal cancer: the effect of epiduralanalgesia on occurrence. Int J Colorectal Dis. 2013 Apr;28(4):485-92. (*)
    39)An emerging new paradigm in opioid withdrawal: a critical role for glia-neuron signaling in the periaqueductal gray. Scientific World Journal. 2012:940613.  
    40)Anaesthetic technique may affect prognosis for ovarian serous adenocarcinoma: a retrospective analysis. Br J Anaesth. 2011 Jun;106(6):814-22. (*)
    41)Mechanisms of antinociceptive effects of ouabain in combination with neostigmine in the rat. Neural regeneration research 2008.3(7): 710-3. (*)
    42)Antinociceptive Synergistic Interaction between Clonidine and Ouabain on Thermal Nociceptive Tests in the Rat. J Pain 2007.8(12): 983-8. (*)
    43)Effects of succinylcholine on spinal antinociception with lidocaine in rats. Acute Pain 2005; 7(1):37-42. (*)
    44)Spinal antinociceptive action of Na+–K+ pump inhibitor ouabain and it interaction with morphine and lidocaine in rats. Anesthesiology 1999; 90: 500-8. (*)

    五、社会任职:
    1.广东省医学会疼痛学会分会第六届主任委员
    2.广东省抗癌协会肿瘤麻醉与镇痛专业委员会荣誉主委
    3.中国心胸血管麻醉学会胸科麻醉分会副主任委员
    4.广东医学会麻醉分会常委
    5.广东省医师学会麻醉分会常委
    6.中华医学会疼痛学分会第七、八届委员会委员
    7.中山大学学报编委
    8.BMC Anesthesiology Associate Editor

    六、编著:
    1.癌症疼痛的临床治疗 人民卫生出版社 副主编
    2.麻醉学考点 科学技术文献出版社 副主编
    3.围麻醉期风险与处理 人民卫生出版社 编委
    4.临床麻醉意外与并发症的预防和处理 人民卫生出版社 编委
    5.现代术后镇痛学 广东科技出版社 编委
    6.胸科肿瘤麻醉学 郑州大学出版社 编委
    7.神经性疼痛诊疗学 郑州大学出版社 编委
    8.2013麻醉学新进展 人民卫生出版社 编委
    9.围术期临床监测手册 人民卫生出版社 编委


    更新日期:2021年2月24日
访客通道
员工通道
关注肿瘤医院
留言建议 ×